Group 1: Energy Storage Industry - Advanced Energy is one of the three leading industries in Changping District, with a focus on innovation in energy storage solutions [1] - Zhonghai Energy is developing iron-chromium flow batteries, which have a 90% water-based electrolyte, significantly reducing fire risks associated with traditional lithium-ion batteries [1][2] - The company has secured multiple billion-level orders and expects to achieve a revenue of 200 million yuan this year, with plans to establish three production bases across the country [2] Group 2: Pharmaceutical Industry - Innovent Biologics has received approval for its new BTK inhibitor, Oubatinib, for treating chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), expanding its market potential [2][3] - The drug is also being explored for use in autoimmune diseases, with several clinical trials progressing to global Phase III [3] - The innovative design of Oubatinib allows for precise targeting of BTK proteins, minimizing side effects and enhancing safety for long-term use in autoimmune conditions [3] Group 3: Synthetic Biology and Advanced Manufacturing - The synthetic biology sector is emerging in Changping, with companies like Weiyuan Synthetic innovating in the production of rare sugars like allulose through engineered microorganisms [4] - The rapid growth of Weiyuan Synthetic is supported by public service platforms established by the district to aid startups in high-throughput screening and other essential services [4] - The private sector in Changping contributes significantly to the local economy, accounting for over 79.8% of large-scale enterprises and generating substantial tax revenue and employment [4]

Core Insights - The CSI Hong Kong 300 Biopharmaceutical Index (H300 Biopharmaceuticals) reported a value of 958.77 points, showing a significant upward trend [1] - The index has increased by 2.89% over the past month, 34.24% over the past three months, and 47.43% year-to-date [1] - The index is designed to reflect the overall performance of different industries in the Hong Kong market, based on the CSI industry classification standards [1] Index Composition - The CSI Hong Kong 300 Biopharmaceutical Index consists entirely of securities listed on the Hong Kong Stock Exchange, with a 100% allocation [1] - The index is composed solely of the biopharmaceutical sector, indicating a focused investment strategy [1] Index Adjustment Mechanism - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made in response to significant events affecting sample companies [2] - Events such as delisting, mergers, or changes in industry classification will prompt corresponding adjustments to the index samples [2]

| A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-015 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 便利投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东大会提醒服务，委托上证信息通过发送智能短信等形式，根据股权登记日 的股东名册主动提醒股东参会投票，向每一位投资者主动推送股东大会参会邀请、 议案情况等信息。投资者在收到智能短信后，可根据《上市公司股东会网络投票 一键通服务用户使用手册》（下载链接：https://vote.sseinfo.com/i/yjt_help.pdf）的 提示步骤直接投票，如遇拥堵等情况，仍可通过原有的交易系统投票平台和互联 网投票平台进行投票。 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向公司反馈，感谢广大投资者对公司的关注与支持！ 特此公告。 诺诚健华医药有限公司董事会 2025 年 5 月 7 日 1 诺诚健华医药有限公司 关于股东大会开设网络投票提 ...

Core Insights - The Chinese innovative drug industry is experiencing a positive trend, with increasing industry prosperity and significant breakthroughs in product development by various companies [1][2][3] - The AACR annual meeting showcased the strength of Chinese innovative drug research, with 126 companies presenting nearly 300 new drug research results [2] - Several companies reported impressive financial results, indicating a recovery and growth in the sector [4][5][6] Industry Developments - The AACR meeting highlighted the growing influence of Chinese innovative drugs, with over 80 ADC studies and nearly 40 bispecific antibody studies presented [2] - Notable approvals include the new BTK inhibitor from Innovent Biologics and the PD-1/VEGF bispecific antibody from Kangfang Biotech, both receiving regulatory approval for cancer treatment [3] - The industry is seeing a trend of improved financial performance, with companies like Heng Rui Pharma reporting a 22.63% increase in revenue and a 47.28% increase in net profit [4] Financial Performance - Heng Rui Pharma achieved a revenue of 27.985 billion yuan, with a net profit of 6.337 billion yuan, reflecting strong growth [4] - Bai Li Tian Heng reported a staggering 936.31% increase in revenue to 5.823 billion yuan, turning a profit due to a significant upfront payment from a global pharmaceutical partner [4] - Shen Zhou Cell's revenue reached 2.513 billion yuan, marking a 33.13% increase, with the company achieving profitability for the first time [5] Market Catalysts - The innovative drug sector is being catalyzed by various factors, including overseas licensing, domestic policy support, and clinical data advancements [7] - Recent policies in Beijing and Shenzhen aim to accelerate innovation in the pharmaceutical industry, offering financial incentives for successful drug approvals [7] - Investment trends show a significant increase in domestic innovative drug financing, with a 51.78% year-on-year growth in March [7] Future Outlook - Industry experts believe that continued policy support will provide better development opportunities for differentiated innovative drugs in China [8] - The focus on innovation and internationalization remains a core strategy for the industry, with expectations for faster approval processes and supportive pricing mechanisms [8]

生物科技板块的强劲表现带动相关主题基金收益飙升。据Wind数据，截至4月30日，在今年来收益率排名前20的权益基金中，9只为医药主题基金，收益率 均在40%以上。其中，长城医药产业精选在一季度大幅加仓医药股，对第一大重仓股泽璟制药增持约1.84万股，对第二大重仓股信达生物增持约4.85万股， 对诺诚健华增持16.2万股，对益方生物、康弘药业等亦有大幅增持。 平安核心优势混合同样在一季度积极调仓，康方生物升为第一大重仓股，增持约4.5万股；诺诚健华新进为前十大重仓股，持有28.08万股。其对百济神州、 百利天恒、艾力斯也有不同程度加仓。知名基金经理葛兰管理的中欧医疗健康混合一季度净值大幅反弹，科伦药业新进入前十大重仓股，迈瑞医疗、东阿阿 胶、华润三九等个股被减持。 【环球网财经综合报道】Wind数据显示，今年以来，港股生物科技板块强势崛起，恒生香港上市生物科技指数（HSHKBIO）累计上涨32.83%，跑赢同期恒 生科技指数。多只细分领域龙头股股价创新高，荣昌生物年内涨幅达到187.5%，三生制药、康宁杰瑞制药-B等涨幅超过120%，信达生物、百济神州、诺诚 健华等涨幅超过40%。 有业内人士表示，2025年或 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, which has shown positive growth in recent months and has a diversified portfolio in the healthcare sector [1][3]. - As of April 30, 2025, the latest net value of the fund is 2.5180 yuan, reflecting a growth of 1.82%. The fund's return over the past month is 2.07%, ranking 41 out of 469 in its category. Over the past three months, the return is 11.71%, ranking 45 out of 467, and since the beginning of the year, the return is 10.49%, ranking 44 out of 465 [1]. - The fund's total assets amount to 2.724 billion yuan as of March 31, 2025, and it was established on November 18, 2014. The fund managers are Zhao Bei and Ding Yang [1]. Group 2 - The top ten holdings of the fund account for a total of 39.79%, with significant investments in companies such as Heng Rui Pharmaceutical (8.90%), WuXi AppTec (5.12%), and Aier Eye Hospital (4.94%) [1]. - Zhao Bei, the fund manager, has extensive experience in the healthcare sector, having been with ICBC Credit Suisse Asset Management since 2010 and managing the healthcare fund since its inception in 2014. Ding Yang, the co-manager, has a strong academic background and joined the firm in 2017 [2].

Core Viewpoint - The article highlights the rapid development of the Chinese innovative pharmaceutical company, Nuo Cheng Jian Hua, since its establishment in 2015, showcasing its competitive advantages through continuous innovation and the successful commercialization of its core product, Obinutuzumab [4][5]. Group 1: Company Development - Nuo Cheng Jian Hua has established a rich product pipeline in hematological malignancies, autoimmune diseases, and solid tumors, with its core product, Obinutuzumab, achieving commercialization [4][5]. - The company has successfully listed on both the Hong Kong Stock Exchange and the Sci-Tech Innovation Board, benefiting from supportive policies for innovative drug companies [8][10]. - As of December 31, 2024, Nuo Cheng Jian Hua reported a cash balance of 7.76 billion yuan, indicating strong financial health [12]. Group 2: Product Innovation - Obinutuzumab, a novel BTK inhibitor developed by the company, has received approval for a new indication in first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) [5][7]. - The drug has shown potential effects in treating demyelinating diseases due to its high target selectivity and ability to penetrate the blood-brain barrier [5]. - The company anticipates the approval of five to six innovative drugs in the next three to five years, with three to four products entering international markets [7]. Group 3: Industry Context - The Chinese biopharmaceutical industry has experienced robust growth, supported by favorable policies and a vibrant innovation ecosystem [13]. - Recent measures from the Beijing Municipal Medical Security Bureau aim to enhance the quality of innovative drug development and streamline clinical trial approvals [13][14]. - The industry is expected to see accelerated innovation and commercialization of domestic drugs, driven by policy support and company initiatives [15].

创新药概念持续活跃 百济神州等多股创历史新高 智通财经4月30日电，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制 药、华东医药、恒瑞医药等涨幅靠前。消息面上，2025年一季度，已经出现了超20笔涉及中国药企全球 授权的交易，BD交易有望在今年再创新高。 ...

此外，诺诚健华还履行社会责任，在乡村振兴、教育支持、患者关爱等方面开展公益活动，向内蒙古太 卜寺旗和阿鲁科尔沁旗捐赠图书，向青海省玉树州曲麻莱县捐赠爱心洗漱包等。其还与患者组织合作， 传递淋巴瘤患者的坚韧与力量，从而激发社会各界对患者的关注与支持。 对此，诺诚健华联合创始人、董事长兼首席执行官崔霁松博士说："2025年是我们发展进程中的第十 年，站在新的起点，我们将继续秉承'科学驱动创新，患者所需为本'的理念，以更开放的姿态拥抱行业 变革，加速推进研发、商业化和全球化，持续完善质量管理体系，深入践行绿色低碳发展战略，积极履 行企业社会责任。" 4月30日，北京生物医药高科技公司诺诚健华正式发布2024年环境、社会和公司治理（ESG）报告，这 也是公司连续第六年发布ESG报告。2024年，公司将ESG理念融入企业发展战略，在创新研发中突破边 界，在质量管控中精益求精，在绿色转型中勇担使命，在公益活动中传递温度，努力实现公司经济效益 与社会效益的双赢，持续为利益相关方创造长期价值。 今年其ESG报告包括"诚信经营 行稳致远""绿色发展 守护未来""品质争先 进而有为""关爱员工 以人为 本""社会互助 和谐前行" ...

此 乃 要 件 请 即 处 理 阁下如对本通函任何方面或应采取的行动有任何疑问，应咨询股票经纪或其他注册证券交易商、银行经理、 律师、专业会计师或其他专业顾问。 阁下如已将名下所有诺诚健华医药有限公司的股份出售或转让，应立即将本通函交予买主或承让人或经手 买卖的银行、股票经纪或其他代理商，以便转交买主或承让人。 香港交易及结算所有限公司及香港联合交易所有限公司对本通函的内容概不负责，对其准确性或完整性亦 不发表任何声明，并明确表示，概不就本通函全部或任何部分内容而产生或因倚赖该等内容而引致的任何损 失承担任何责任。 InnoCare Pharma Limited 诺诚健华医药有限公司 （于开曼群岛注册成立的有限公司） （股份代号：9969） (1) 2024年年度报告； (2) 董事会2024年度工作报告； (3) 2024年度公司利润分配计划； (4) 建议发行及购回股份的一般授权； (5) 重选退任董事； (6) 重新委任核数师； (7) 建议为董事及高级管理层购买责任保险； (8) 建议更新人民币股份发行募集资金用途； 及 (9) 股东周年大会通告 诺诚健华医药有限公司谨订于2025年6月20日（星期五 ...